Syntopix announces agreement with Sinclair Pharma

SKIN treatment development specialist Syntopix today announced an agreement with an international speciality pharma company to develop a new product.

Bradford-based Syntopix, which develops treatments for skin conditions such as acne, will work with Sinclair Pharma on the identification of an antimicrobial compound to synergise and augment the activity of a key product for Sinclair.

Sinclair is a leading skin and mouth disease specialist with sales and marketing operations across Europe.
 
Should the collaboration result in a product that reaches commercialisation, financial gains from the sales will be shared between the two companies.

Dr Stephen Jones, chief executive of of Syntopix, said: “We are delighted to be entering into this collaboration with Sinclair. I am very confident that its proprietary compound will be complemented and enhanced by some of the compounds that Syntopix has been identifying in this area over several years. We look forward to sharing exciting compounds and technical expertise with the intention of developing a market leading healthcare product.”